Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Once-daily cystic fibrosis drug offers simpler home treatment and fewer side effects for children

11.02.2005


Nottingham researchers have found a way to treat children with cystic fibrosis (CF), which could reduce their side effects and see more young patients treated at home.



Experts at The University of Nottingham organised the largest successful clinical trial in the UK looking at cystic fibrosis in an attempt to discover whether a common antibiotic used to treat the condition could be administered just once a day instead of the usual three daily doses.

The recommendations from the study, which included CF patients from Nottingham City Hospital and will be published in The Lancet this week, could lead to simpler home treatment with less disruption to patients and their families.


The study was funded with £404,464 from the Cystic Fibrosis Trust, as part of their UK-wide work to improve clinical support for people with cystic fibrosis and help find a cure for this disease.

One of the patients who took part in the study was 17-year-old Kayleigh Boden. Kayleigh, an A-level student from Welton near Lincoln, found that her side effects reduced and she liked being able to administer her drugs just once a day at 4pm rather than the usual three times a day, including a midnight shift.

“The drugs usually lead to tinnitus and headaches and my eyes are affected, but I definitely suffered fewer side effects during the trial,” she added.

Kayleigh hopes that administering her drugs just once a day will help her to effectively manage her condition while allowing her to lead an active life that will include sitting her exams in the summer and, hopefully, achieving her ambition of going to university to train as a quantity surveyor.

Cystic fibrosis is the UK’s most common life-threatening inherited disease. Sufferers have difficulty in digesting food and are vulnerable to chronic chest infections. Every week five babies are born with CF and three people die from the condition — 90 per cent from the lung damage, which often results from chronic chest infections.

Patients are frequently given prolonged courses of intravenous antibiotics to treat chronic chest infections, often for two weeks or more. This treatment may be needed every few months and can interfere with children’s schooling or adults studying or getting work. Sometimes intravenous treatment is given at home rather than in hospital to make this easier. However, administering this treatment puts an extra strain on parents, partners or the patient themselves.

In an effort to make home treatment easier, the team in the University’s Division of Respiratory Medicine, led by Professor Alan Knox and Dr Alan Smyth, organised the TOPIC (Tobramycin Once-daily Prescribing In Cystic fibrosis) national trial.

The researchers are based at the study’s co-ordinating centre, Nottingham City Hospital, where they care for 80 children with CF and travel out to see another 80 children at five other hospitals. The hospital also has a busy adult clinic treating more than 100 patients.

The study looked at tobramycin, a commonly-used antibiotic, to see if it would be effective when given once a day rather than the usual three times daily treatment. The drug can potentially lead to reduced kidney function and hearing loss. However, the TOPIC team found that once daily treatment worked just as well and seemed to have fewer side effects in children.

Rosie Barnes, Chief Executive of the Cystic Fibrosis Trust, said: “This is a very encouraging and exciting piece of research not least because of the immediate impact on patients. It will help relieve what is very time-consuming care and reduce the amount of time spent taking the required dose of antibiotics.”

The team is now looking at new ways to help people with CF. Current projects are looking at the role of garlic capsules against chest infection and whether home treatment can be simplified further by giving a second antibiotic as a 24-hour infusion through a small pump device.

Dr Alan Smyth | alfa
Further information:
http://www.nottingham.ac.uk

More articles from Studies and Analyses:

nachricht Do microplastics harbour additional risks by colonization with harmful bacteria?
05.04.2018 | Leibniz-Institut für Ostseeforschung Warnemünde

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Scientists re-create brain neurons to study obesity and personalize treatment

20.04.2018 | Health and Medicine

Spider silk key to new bone-fixing composite

20.04.2018 | Materials Sciences

Clear as mud: Desiccation cracks help reveal the shape of water on Mars

20.04.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>